Skip to main content
Erschienen in: Reactions Weekly 1/2021

01.10.2021 | Case report

Nivolumab/pembrolizumab

Rheumatoid vasculitis, acute heart failure with reduced ejection fraction and interstitial lung disease: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Kullberg SA, et al. Programmed cell death protein 1 inhibitor-induced recalcitrant mixed small and medium vessel vasculitis. Dermatology Online Journal 26: No. 9, 15 Sep 2020 Kullberg SA, et al. Programmed cell death protein 1 inhibitor-induced recalcitrant mixed small and medium vessel vasculitis. Dermatology Online Journal 26: No. 9, 15 Sep 2020
Metadaten
Titel
Nivolumab/pembrolizumab
Rheumatoid vasculitis, acute heart failure with reduced ejection fraction and interstitial lung disease: case report
Publikationsdatum
01.10.2021
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2021
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-021-04385-9

Weitere Artikel der Ausgabe 1/2021

Reactions Weekly 1/2021 Zur Ausgabe

Case report

Naproxen

Case report

Alteplase/plasma

Case report

Pembrolizumab

Case report

Valproic-acid